Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease
© 2021 John Wiley & Sons Ltd..
BACKGROUND: Intestinal ultrasound (IUS) is a valuable tool for assessment of Crohn's disease (CD). However, there is no widely accepted luminal disease activity index.
AIMS: To identify appropriate IUS protocols, indices, items, and scoring methods for measurement of luminal CD activity and integration of IUS in CD clinical trials.
METHODS: An expert international panel of adult and paediatric gastroenterologists (n = 15) and radiologists (n = 3) rated the appropriateness of 120 statements derived from literature review and expert opinion (scale of 1-9) using modified RAND/UCLA methodology. Median panel scores of 1 to ≤3.5, >3.5 to <6.5 and ≥6.5 to 9 were considered inappropriate, uncertain and appropriate ratings respectively. The statement list and survey results were discussed prior to voting.
RESULTS: A total of 91 statements were rated appropriate with agreement after two rounds of voting. Items considered appropriate measures of disease activity were bowel wall thickness (BWT), vascularity, stratification and mesenteric inflammatory fat. There was uncertainty if any of the existing IUS disease activity indices were appropriate for use in CD clinical trials. Appropriate trial applications for IUS included patient recruitment qualification when diseased segments cannot be adequately assessed by ileocolonoscopy and screening for exclusionary complications. At outcome assessment, remission endpoints including BWT and vascularity, with or without mesenteric inflammatory fat, were considered appropriate. Components of an ideal IUS disease activity index were identified based upon panel discussions.
CONCLUSIONS: The panel identified appropriate component items and applications of IUS for CD clinical trials. Empiric evidence, and development and validation of an IUS disease activity index are needed.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2021 Apr;53(8):948-949. - PMID 33745169 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 53(2021), 8 vom: 28. Apr., Seite 873-886 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goodsall, Thomas M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 19.04.2021 Date Revised 19.04.2021 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2021 Apr;53(8):948-949. - PMID 33745169 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.16288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321991176 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321991176 | ||
| 003 | DE-627 | ||
| 005 | 20231225181100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.16288 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM321991176 | ||
| 035 | |a (NLM)33641221 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goodsall, Thomas M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2021 | ||
| 500 | |a Date Revised 19.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2021 Apr;53(8):948-949. - PMID 33745169 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Intestinal ultrasound (IUS) is a valuable tool for assessment of Crohn's disease (CD). However, there is no widely accepted luminal disease activity index | ||
| 520 | |a AIMS: To identify appropriate IUS protocols, indices, items, and scoring methods for measurement of luminal CD activity and integration of IUS in CD clinical trials | ||
| 520 | |a METHODS: An expert international panel of adult and paediatric gastroenterologists (n = 15) and radiologists (n = 3) rated the appropriateness of 120 statements derived from literature review and expert opinion (scale of 1-9) using modified RAND/UCLA methodology. Median panel scores of 1 to ≤3.5, >3.5 to <6.5 and ≥6.5 to 9 were considered inappropriate, uncertain and appropriate ratings respectively. The statement list and survey results were discussed prior to voting | ||
| 520 | |a RESULTS: A total of 91 statements were rated appropriate with agreement after two rounds of voting. Items considered appropriate measures of disease activity were bowel wall thickness (BWT), vascularity, stratification and mesenteric inflammatory fat. There was uncertainty if any of the existing IUS disease activity indices were appropriate for use in CD clinical trials. Appropriate trial applications for IUS included patient recruitment qualification when diseased segments cannot be adequately assessed by ileocolonoscopy and screening for exclusionary complications. At outcome assessment, remission endpoints including BWT and vascularity, with or without mesenteric inflammatory fat, were considered appropriate. Components of an ideal IUS disease activity index were identified based upon panel discussions | ||
| 520 | |a CONCLUSIONS: The panel identified appropriate component items and applications of IUS for CD clinical trials. Empiric evidence, and development and validation of an IUS disease activity index are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Jairath, Vipul |e verfasserin |4 aut | |
| 700 | 1 | |a Feagan, Brian G |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Claire E |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Tran M |e verfasserin |4 aut | |
| 700 | 1 | |a Guizzetti, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Asthana, Anil K |e verfasserin |4 aut | |
| 700 | 1 | |a Begun, Jakob |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 700 | 1 | |a Friedman, Antony B |e verfasserin |4 aut | |
| 700 | 1 | |a Kucharzik, Torsten |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Lewindon, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Maaser, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Novak, Kerri L |e verfasserin |4 aut | |
| 700 | 1 | |a Rimola, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Kirstin M |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Stuart A |e verfasserin |4 aut | |
| 700 | 1 | |a White, Lauren S |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkens, Rune |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Stephanie R |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Emily K |e verfasserin |4 aut | |
| 700 | 1 | |a Bryant, Robert V |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Christopher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 53(2021), 8 vom: 28. Apr., Seite 873-886 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:8 |g day:28 |g month:04 |g pages:873-886 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.16288 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 8 |b 28 |c 04 |h 873-886 | ||